2020
Epidemiology and Microbiology of Outpatient Cases of Carbapenem-Resistant Enterobacteriaceae in Connecticut During 2018
Gupta S, Leung V, Maloney M, Macierowski B, Banach D. Epidemiology and Microbiology of Outpatient Cases of Carbapenem-Resistant Enterobacteriaceae in Connecticut During 2018. Infection Control And Hospital Epidemiology 2020, 41: s216-s216. DOI: 10.1017/ice.2020.759.Peer-Reviewed Original ResearchCarbapenem-resistant EnterobacteriaceaeState public health laboratoriesCRE infectionsOutpatient settingOutpatient casesCRE casesClinical managementOral antimicrobialsAntimicrobial susceptibilityClinical CRE isolatesCRE-positive culturesInfectious disease consultationPositive CRE cultureMedian patient agePrimary care settingInfection control practicesAdditional clinical informationE. coli infectionAspects of treatmentPublic health laboratoriesLocation of presentationDifferent outpatient settingsGene detection resultsCRE cultureID consultation
2018
2411. Expanded Susceptibility and Resistance Mechanism Testing Among Carbapenem-Resistant Enterobacteriaceae in Connecticut, 2017
Durante A, Maloney M, Leung V, Macierowski B, Noel D, Razeq J, Banach D. 2411. Expanded Susceptibility and Resistance Mechanism Testing Among Carbapenem-Resistant Enterobacteriaceae in Connecticut, 2017. Open Forum Infectious Diseases 2018, 5: s721-s721. PMCID: PMC6253689, DOI: 10.1093/ofid/ofy210.2064.Peer-Reviewed Original ResearchState public health laboratoriesLaboratory Standards Institute breakpointsPolymerase chain reaction testingReal-time polymerase chain reaction testingCeftazidime/avibactamCarbapenem-resistant EnterobacteriaceaePublic health laboratoriesCRE isolatesEmpiric treatmentCP-CRECarbapenemase testingReaction testingHealth laboratoriesCarbapenemase productionCarbapenem inactivation methodSusceptibility testingCommon carbapenemasesBroth microdilutionNon-CPDisk diffusionInactivation methodCreAntibiogramClinicalAvibactam2396. Fosfomycin Resistance Among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017
Snayd M, Leung V, Maloney M, Durante A, Macierowski B, Noel D, Muyombwe A, Razeq J, Banach D. 2396. Fosfomycin Resistance Among Carbapenem-Resistant Enterobacteriaceae Clinical Isolates in Connecticut, 2017. Open Forum Infectious Diseases 2018, 5: s714-s715. PMCID: PMC6253430, DOI: 10.1093/ofid/ofy210.2049.Peer-Reviewed Original ResearchState public health laboratoriesCRE isolatesNonsusceptible isolatesFosfomycin resistanceAntimicrobial Susceptibility Testing (EUCAST) criteriaCarbapenem-resistant Enterobacteriaceae infectionsOlder patient ageLimited treatment optionsResistance risk factorsSubstantial proportionEnterobacteriaceae clinical isolatesFosfomycin resistance ratePublic health laboratoriesLaboratory Standards InstituteSusceptibility testing criteriaCRE patientsPatient ageEnterobacteriaceae infectionsTreatment optionsRisk factorsResistance ratesWarrants evaluationCarbapenem resistanceBlaKPC geneCLSI criteria